Search research articles
Contact Us
Filters
Showing results (181-190 of 217) with videos related to
Page
of 22
Sort By:
British Journal of Clinical Pharmacology
|
January 1, 1988
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin
I A Choonara, R G Malia, B P Haynes, et al.
Blood
|
February 7, 2002
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
Sharon L Barrans, Ian Carter, Roger G Owen, et al.
Genetics
|
September 2, 2008
A random mutagenesis approach to isolate dominant-negative yeast sec1 mutants reveals a functional role for domain 3a in yeast and mammalian Sec1/Munc18 proteins
Alan Boyd, Leonora F Ciufo, Jeff W Barclay, et al.
Plos One
|
March 30, 2011
Structure-function study of mammalian Munc18-1 and C. elegans UNC-18 implicates domain 3b in the regulation of exocytosis
Margaret E Graham, Gerald R Prescott, James R Johnson, et al.
Breast Cancer Research and Treatment
|
December 1, 1993
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer
S R Johnston, B P Haynes, N P Sacks, et al.
The European Journal of Neuroscience
|
August 14, 2010
Decoding glutamate receptor activation by the Ca2+ sensor protein hippocalcin in rat hippocampal neurons
A V Dovgan, V P Cherkas, A R Stepanyuk, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
B P Haynes, M Jarman, M Dowsett, et al.
Journal of the National Cancer Institute
|
March 8, 2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
James M Rae, Suzy Drury, Daniel F Hayes, et al.
British Journal of Haematology
|
November 19, 2015
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis
Mark J Bishton, Simon Hughes, Faith Richardson, et al.
Cancer Research
|
March 1, 1995
Idoxifene: report of a phase I study in patients with metastatic breast cancer
R C Coombes, B P Haynes, M Dowsett, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 217) with videos related to
Sort By:
Page
of 22
British Journal of Clinical Pharmacology
|
January 1, 1988
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin
I A Choonara, R G Malia, B P Haynes, et al.
Blood
|
February 7, 2002
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
Sharon L Barrans, Ian Carter, Roger G Owen, et al.
Genetics
|
September 2, 2008
A random mutagenesis approach to isolate dominant-negative yeast sec1 mutants reveals a functional role for domain 3a in yeast and mammalian Sec1/Munc18 proteins
Alan Boyd, Leonora F Ciufo, Jeff W Barclay, et al.
Plos One
|
March 30, 2011
Structure-function study of mammalian Munc18-1 and C. elegans UNC-18 implicates domain 3b in the regulation of exocytosis
Margaret E Graham, Gerald R Prescott, James R Johnson, et al.
Breast Cancer Research and Treatment
|
December 1, 1993
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer
S R Johnston, B P Haynes, N P Sacks, et al.
The European Journal of Neuroscience
|
August 14, 2010
Decoding glutamate receptor activation by the Ca2+ sensor protein hippocalcin in rat hippocampal neurons
A V Dovgan, V P Cherkas, A R Stepanyuk, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
B P Haynes, M Jarman, M Dowsett, et al.
Journal of the National Cancer Institute
|
March 8, 2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
James M Rae, Suzy Drury, Daniel F Hayes, et al.
British Journal of Haematology
|
November 19, 2015
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis
Mark J Bishton, Simon Hughes, Faith Richardson, et al.
Cancer Research
|
March 1, 1995
Idoxifene: report of a phase I study in patients with metastatic breast cancer
R C Coombes, B P Haynes, M Dowsett, et al.
Page
of 22